BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 20639863)

  • 1. Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
    Ito T; Kwon HY; Zimdahl B; Congdon KL; Blum J; Lento WE; Zhao C; Lagoo A; Gerrard G; Foroni L; Goldman J; Goh H; Kim SH; Kim DW; Chuah C; Oehler VG; Radich JP; Jordan CT; Reya T
    Nature; 2010 Aug; 466(7307):765-8. PubMed ID: 20639863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
    Griner LN; Reuther GW
    Cancer Biol Ther; 2010 Nov; 10(10):979-82. PubMed ID: 21084860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
    Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia.
    Hattori A; Tsunoda M; Konuma T; Kobayashi M; Nagy T; Glushka J; Tayyari F; McSkimming D; Kannan N; Tojo A; Edison AS; Ito T
    Nature; 2017 May; 545(7655):500-504. PubMed ID: 28514443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
    Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
    Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia with t(7;11)(p15;p15).
    Yamamoto K; Nakamura Y; Saito K; Furusawa S
    Br J Haematol; 2000 May; 109(2):423-6. PubMed ID: 10848835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
    Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
    Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
    Shoumariyeh K; Hussung S; Niemöller C; Bleul S; Veratti P; Follo M; Riba J; Philipp U; Palmer JM; Pfeifer D; Pantic M; Meggendorfer M; Hackanson B; Finke J; Haferlach T; Duyster J; Miething C; Becker H; von Bubnoff N
    Br J Haematol; 2020 Sep; 190(6):e339-e343. PubMed ID: 32579287
    [No Abstract]   [Full Text] [Related]  

  • 10. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
    Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
    Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis.
    Abollo-Jiménez F; Campos-Sánchez E; Toboso-Navasa A; Vicente-Dueñas C; González-Herrero I; Alonso-Escudero E; González M; Segura V; Blanco O; Martínez-Climent JA; Sánchez-García I; Cobaleda C
    Cell Cycle; 2014; 13(11):1717-26. PubMed ID: 24675889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells.
    García-Alegría E; Lafita-Navarro MC; Aguado R; García-Gutiérrez L; Sarnataro K; Ruiz-Herguido C; Martín F; Bigas A; Canelles M; León J
    Cancer Lett; 2016 May; 375(1):92-99. PubMed ID: 26944313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
    Nakahara F; Sakata-Yanagimoto M; Komeno Y; Kato N; Uchida T; Haraguchi K; Kumano K; Harada Y; Harada H; Kitaura J; Ogawa S; Kurokawa M; Kitamura T; Chiba S
    Blood; 2010 Apr; 115(14):2872-81. PubMed ID: 19861684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
    Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
    FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.
    Matte-Martone C; Venkatesan S; Tan HS; Athanasiadis I; Chang J; Pavisic J; Shlomchik WD
    J Immunol; 2011 Aug; 187(4):1653-63. PubMed ID: 21768400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
    Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
    Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23).
    Barbouti A; Höglund M; Johansson B; Lassen C; Nilsson PG; Hagemeijer A; Mitelman F; Fioretos T
    Cancer Res; 2003 Mar; 63(6):1202-6. PubMed ID: 12649177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
    Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
    Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.